Related Experiment Video

Updated: Jul 13, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

[Glibenclamide in the treatment for gestational diabetes mellitus in a compared study to insulin]

Jean C Silva1, Anna M Bertini, Wladimir Taborda

  • 1Maternidade Darcy Vargas, Universidade da Região de Joinville-UNIVILLE, 89203-050 Joinville, SC. jeancs01@terra.com.br

Arquivos Brasileiros De Endocrinologia E Metabologia
|August 9, 2007
PubMed

Insights

Glibenclamide use in gestational diabetes mellitus (GDM) resulted in higher newborn birth weight and increased neonatal hypoglycemia compared to insulin. Careful patient selection is advised for GDM treatment.

Area of Science:

  • Obstetrics and Gynecology
  • Endocrinology
  • Neonatology

Background:

  • Gestational diabetes mellitus (GDM) requires effective management to prevent adverse maternal and neonatal outcomes.
  • Oral hypoglycemic agents are increasingly considered as alternatives to insulin for GDM treatment.

Purpose of the Study:

  • To compare glibenclamide with insulin for GDM management.
  • To assess the impact of glibenclamide versus insulin on newborn birth weight and neonatal glycemia.

Main Methods:

  • A randomized, open-label clinical trial involving 72 pregnant women with GDM requiring pharmacotherapy.
  • Participants were allocated to either insulin or glibenclamide treatment groups.

Main Results:

  • Maternal glucose levels were similar between groups, but glibenclamide group had higher OGTT results.
  • Newborns in the glibenclamide group exhibited higher birth weight and increased incidence of macrosomia and hypoglycemia.
  • 18.75% of patients on glibenclamide did not achieve glycemic control even at maximum dosage.

Conclusions:

  • Glibenclamide may be a first-line option for GDM, but carries risks of increased birth weight and neonatal hypoglycemia.
  • The study highlights the need for careful consideration of glibenclamide's risks versus benefits in GDM management.
Abstract

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...